ValuEngine upgraded shares of AVITA MED LTD/S (NASDAQ:RCEL) from a hold rating to a buy rating in a research report report published on Saturday, ValuEngine reports.

Several other research firms have also recently weighed in on RCEL. BTIG Research restated a buy rating and set a $8.00 price target on shares of AVITA MED LTD/S in a report on Thursday, June 18th. Oppenheimer initiated coverage on shares of AVITA MED LTD/S in a report on Monday, June 15th. They set a buy rating and a $9.00 price target on the stock. Lake Street Capital restated a buy rating and set a $12.00 price target on shares of AVITA MED LTD/S in a report on Thursday, March 5th. Finally, Zacks Investment Research cut shares of AVITA MED LTD/S from a buy rating to a hold rating in a research note on Tuesday, June 23rd. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $8.88.

NASDAQ:RCEL opened at $6.09 on Friday. AVITA MED LTD/S has a one year low of $5.20 and a one year high of $55.35. The company has a market cap of $560.32 million, a PE ratio of -15.62 and a beta of 1.23. The firm has a 50-day moving average of $6.19 and a 200-day moving average of $7.40. The company has a debt-to-equity ratio of 0.03, a current ratio of 15.36 and a quick ratio of 15.22.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. purchased a new stake in shares of AVITA MED LTD/S during the 1st quarter valued at approximately $29,000. UBS Group AG bought a new stake in AVITA MED LTD/S during the 4th quarter worth approximately $49,000. Larson Financial Group LLC increased its holdings in shares of AVITA MED LTD/S by 77.6% in the 1st quarter. Larson Financial Group LLC now owns 5,985 shares of the company’s stock worth $37,000 after buying an additional 2,616 shares during the last quarter. Bank of America Corp DE bought a new position in shares of AVITA MED LTD/S in the 4th quarter worth $58,000. Finally, Ladenburg Thalmann Financial Services Inc. bought a new position in shares of AVITA MED LTD/S in the 4th quarter worth $64,000. Hedge funds and other institutional investors own 5.52% of the company’s stock.

AVITA MED LTD/S Company Profile

Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin.

Featured Article: What is a conference call?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for AVITA MED LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVITA MED LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.